Updates are available Correction dated 2022-05-17
Click to view Correction: https://doi.org/10.1038/s41467-022-30365-w
-
Authors
Garg, Manik https://orcid.org/0000-0003-0453-2058
Couturier, Dominique-Laurent https://orcid.org/0000-0001-5774-5036
Nsengimana, Jérémie https://orcid.org/0000-0002-3603-4208
Fonseca, Nuno A. https://orcid.org/0000-0003-4832-578X
Wongchenko, Matthew https://orcid.org/0000-0003-1230-7117
Yan, Yibing
Lauss, Martin
Jönsson, Göran B.
Newton-Bishop, Julia
Parkinson, Christine
Middleton, Mark R. https://orcid.org/0000-0003-0167-1685
Bishop, D. Timothy https://orcid.org/0000-0002-8752-8785
McDonald, Sarah
Stefanos, Nikki
Tadross, John https://orcid.org/0000-0002-8424-1252
Vergara, Ismael A. https://orcid.org/0000-0002-2960-2967
Lo, Serigne https://orcid.org/0000-0001-5092-5544
Newell, Felicity https://orcid.org/0000-0003-0469-2705
Wilmott, James S.
Thompson, John F. https://orcid.org/0000-0002-2816-2496
Long, Georgina V.
Scolyer, Richard A. https://orcid.org/0000-0002-8991-0013
Corrie, Pippa
Adams, David J. https://orcid.org/0000-0001-9490-0306
Brazma, Alvis https://orcid.org/0000-0001-5988-7409
Rabbie, Roy https://orcid.org/0000-0002-9195-5659
-
Funding
Funding for this research was provided by:
University of Sydney Medical Foundation
Department of Health | National Health and Medical Research Council
- License Information
-
More Information
Article History
Received: 10 March 2020
Accepted: 15 January 2021
First Online: 18 February 2021
Change Date: 17 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-30365-w
Competing interests
: P.C. is an advisory board member at Roche. M.W./Y.Y. are employees and stockholders at Roche/Genentech. D.J.A. is a consultant at Microbiotica. R.A.S. has received fees for professional services from Qbiotics, Novartis, MSD Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. G.V.L. is consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, QBiotics Group Limited, Regeneron Pharmaceuticals Inc, SkylineDX B.V. J.F.T. has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel support from GlaxoSmithKline and Provectus Inc. All other authors report no conflicts of interest.
